3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Withdrawn
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Classical hematology
1
Conditions
Hematologic Neoplasms
1
Febrile Neutropenia
1
Interventions
Epoetin Alfa
38
Darbepoetin alfa
30
epoetin beta
10
Rivaroxaban
9
olaparib
5
eltrombopag
5
apixaban
5
Heparin, Low-Molecular-Weight
5
pegylated granulocyte colony-stimulating factor
4
pegfilgrastim
4
emicizumab
4
Gemcitabine
4
Filgrastim
4
Dalteparin
4
Cyclophosphamide
4
AP 1903 reagent
4
romiplostim
3
peginesatide
3
luspatercept
3
hetrombopag
3
hematide
3
Vancomycin
3
ON 01910
3
Enoxaparin
3
Azacitidine
3
ACE-011
3
venetoclax
2
telapristone acetate
2
roxadustat
2
iron isomaltoside 1000
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
ceftolozane, tazobactam drug combination
×
Classical hematology
×
Clear all
NCT05061654
2023-08-14
CEF-10
Hamad Medical Corporation
Phase 4
Withdrawn